DENVER, Colo., 14 June, 2024 (247marketnews.com) – (NASDAQ:BPTH) are discussed in this article.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) has seen a significant surge in its stock price, marking a remarkable 21.10% increase in the pre-market session, trading at $2.404. This upward momentum follows the company’s recent presentation of encouraging interim data from its Phase 2 clinical trial at the esteemed 2024 European Hematology Association (EHA) Congress. The event, held on June 14, 2024, showcased Bio-Path’s innovative approach to cancer drug development, particularly focusing on acute myeloid leukemia (AML).
During the congress, Bio-Path unveiled promising results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax. By leveraging its proprietary DNAbilize® liposomal delivery and antisense technology, the company aims to provide targeted nucleic acid drugs for cancer treatment, with a specific emphasis on AML.
The presentation at the EHA Congress emphasized the potential of Bio-Path’s novel treatment regimen to address the unmet medical needs of AML patients. Through a multi-modal approach involving prexigebersen, decitabine, and venetoclax, Bio-Path is working towards improving treatment outcomes and offering new possibilities for individuals combating this challenging disease.
These interim results underscore Bio-Path’s commitment to advancing precision medicine and enhancing patient outcomes in the field of oncology. With a focus on innovation and dedicated research efforts, Bio-Path continues its mission to develop effective and targeted cancer therapies that could revolutionize cancer treatment strategies.
For more information on Bio-Path’s transformative research initiatives and future developments, stakeholders are encouraged to visit the company’s official website and stay informed about forthcoming announcements on this groundbreaking progress.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com